Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16,434 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial.
Hisamatsu T, Kunisaki R, Nakamura S, Tsujikawa T, Hirai F, Nakase H, Watanabe K, Yokoyama K, Nagahori M, Kanai T, Naganuma M, Michimae H, Andoh A, Yamada A, Yokoyama T, Kamata N, Tanaka S, Suzuki Y, Hibi T, Watanabe M; CERISIER Trial group. Hisamatsu T, et al. Among authors: suzuki y. Intest Res. 2018 Jul;16(3):494-498. doi: 10.5217/ir.2018.16.3.494. Epub 2018 Jul 27. Intest Res. 2018. PMID: 30090050 Free PMC article. No abstract available.
Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries.
Kobayashi T, Hisamatsu T, Suzuki Y, Ogata H, Andoh A, Araki T, Hokari R, Iijima H, Ikeuchi H, Ishiguro Y, Kato S, Kunisaki R, Matsumoto T, Motoya S, Nagahori M, Nakamura S, Nakase H, Tsujikawa T, Sasaki M, Yokoyama K, Yoshimura N, Watanabe K, Katafuchi M, Watanabe M, Hibi T. Kobayashi T, et al. Among authors: suzuki y. Intest Res. 2018 Apr;16(2):168-177. doi: 10.5217/ir.2018.16.2.168. Epub 2018 Apr 30. Intest Res. 2018. PMID: 29743830 Free PMC article. Review.
Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy: a multicenter study from Japan.
Komoto S, Motoya S, Nishiwaki Y, Matsui T, Kunisaki R, Matsuoka K, Yoshimura N, Kagaya T, Naganuma M, Hida N, Watanabe M, Hibi T, Suzuki Y, Miura S, Hokari R; Japanese study group for pregnant women with IBD. Komoto S, et al. Among authors: suzuki y. Intest Res. 2016 Apr;14(2):139-45. doi: 10.5217/ir.2016.14.2.139. Epub 2016 Apr 27. Intest Res. 2016. PMID: 27175114 Free PMC article.
Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial.
Matsumoto T, Motoya S, Watanabe K, Hisamatsu T, Nakase H, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T; DIAMOND study group. Matsumoto T, et al. Among authors: suzuki y. J Crohns Colitis. 2016 Nov;10(11):1259-1266. doi: 10.1093/ecco-jcc/jjw152. Epub 2016 Aug 26. J Crohns Colitis. 2016. PMID: 27566367 Clinical Trial.
Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment.
Park DI, Hisamatsu T, Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK. Park DI, et al. Among authors: suzuki y. Intest Res. 2018 Jan;16(1):4-16. doi: 10.5217/ir.2018.16.1.4. Epub 2018 Jan 18. Intest Res. 2018. PMID: 29422793 Free PMC article. Review.
Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management.
Park DI, Hisamatsu T, Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK. Park DI, et al. Among authors: suzuki y. Intest Res. 2018 Jan;16(1):17-25. doi: 10.5217/ir.2018.16.1.17. Epub 2018 Jan 18. Intest Res. 2018. PMID: 29422794 Free PMC article. Review.
Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance Therapy.
Motoya S, Watanabe M, Wallace K, Lazar A, Nishimura Y, Ozawa M, Thakkar R, Robinson AM, Singh RSP, Mostafa NM, Suzuki Y, Hibi T. Motoya S, et al. Among authors: suzuki y. Inflamm Intest Dis. 2018 Jul;2(4):228-235. doi: 10.1159/000486786. Epub 2018 May 15. Inflamm Intest Dis. 2018. PMID: 30221150 Free PMC article.
Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2).
Hisamatsu T, Kato S, Kunisaki R, Matsuura M, Nagahori M, Motoya S, Esaki M, Fukata N, Inoue S, Sugaya T, Sakuraba H, Hirai F, Watanabe K, Kanai T, Naganuma M, Nakase H, Suzuki Y, Watanabe M, Hibi T, Nojima M, Matsumoto T; DIAMOND2 Study Group. Hisamatsu T, et al. Among authors: suzuki y. J Gastroenterol. 2019 Oct;54(10):860-870. doi: 10.1007/s00535-019-01582-w. Epub 2019 Apr 30. J Gastroenterol. 2019. PMID: 31041545 Clinical Trial.
16,434 results
You have reached the last available page of results. Please see the User Guide for more information.